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Abstract
Background: Cefotaxime plays an important role in the treatment of patients with bacteremia due to
Enterobacteriaceae, although cefotaxime resistance is reported to be increasing in association with
extended-spectrum β-lactamase (ESBL) and AmpC β-lactamase (AmpC).
Methods: We conducted a case-control study in a Japanese university hospital between 2011 and 2012. We
assessed the risk factors and clinical outcomes of bacteremia due to cefotaxime-non-susceptible Enterobacteriaceae
(CTXNS-En) and analyzed the resistance mechanisms.
Results: Of 316 patients with Enterobacteriaceae bacteremia, 37 patients with bacteremia caused by CTXNS-En were
matched to 74 patients who had bacteremia caused by cefotaxime-susceptible Enterobacteriaceae (CTXS-En). The
most common CTXNS-En was Escherichia coli (43%), followed by Enterobacter spp. (24%) and Klebsiella spp. (22%).
Independent risk factors for CTXNS-En bacteremia included previous infection or colonization of CTXNS-En, cardiac
disease, the presence of intravascular catheter and prior surgery within 30 days. Patients with CTXNS-En bacteremia
were less likely to receive appropriate empirical therapy and to achieve a complete response at 72 h than patients
with CTXS-En bacteremia. Mortality was comparable between CTXNS-En and CTXS-En patients (5 vs. 3%). CTXNS-En
isolates exhibited multidrug resistance but remained highly susceptible to amikacin and meropenem. CTX-M-type
ESBLs accounted for 76% of the β-lactamase genes responsible for CTXNS E. coli and Klebsiella spp. isolates, followed by
plasmid-mediated AmpC (12%). Chromosomal AmpC was responsible for 89% of CTXNS Enterobacter spp. isolates.
Conclusions: CTXNS-En isolates harboring ESBL and AmpC caused delays in appropriate therapy among bacteremic
patients. Risk factors and antibiograms may improve the selection of appropriate therapy for CTXNS-En bacteremia.
Prevalent mechanisms of resistance in CTXNS-En were ESBL and chromosomal AmpC.
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Background
Third-generation cephalosporins, such as cefotaxime,
form an important part of empirical antimicrobial ther-
apy for infections caused by members of the Enterobac-
teriaceae family, such as Escherichia coli and Klebsiella
pneumoniae. Third-generation cephalosporins can be a
reasonable choice even for patients with nosocomial
infections who have non-severe illness. However, a re-
cent increase in the prevalence of third-generation
cephalosporin-resistance has challenged the use of this
therapy [1]. β-Lactamases have been recognized as the
main cause of cephalosporin resistance among Entero-
bacteriaceae. The most common β-lactamases are
extended-spectrum β-lactamases (ESBLs), followed by
AmpC β-lactamases [2].
When gram-negative bacteria is grown in blood cul-
ture, the type of positive blood culture bottle (aerobic or
anaerobic) and the gram stain findings help us to
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estimate if the bacteria belongs to the Enterobacteriaceae
family or are non-fermenting gram-negative bacteria. It
is impossible to determine the exact genus or species
without emerging rapid identification technologies, such
as matrix-assisted laser desorption-ionization time-of
flight mass spectrometry. Therefore, we usually determine
a regimen of empiric therapy targeting Enterobacteriaceae,
not specific species (e.g., E. coli). However, most studies re-
garding bacteremia due to third-generation cephalosporin-
non-susceptible Enterobacteriaceae have focused on E. coli
and K. pneumoniae [2–5]. A few studies have investigated
Enterobacteriaceae as a group. Rottier et al. assessed risk
factors for bacteremia by third-generation cephalosporin-
non-susceptible Enterobacteriaceae [6], and two studies
analyzed resistance mechanisms [7, 8]. Data from these
bacteremias from Japan have not been reported. We con-
ducted this study to determine the risk factors and clinical
outcomes associated with bacteremia due to cefotaxime-
non-susceptible Enterobacteriaceae (CTXNS-En). In
addition, we elucidated the epidemiology of β-lactamases
that confer resistance to CTXNS-En.
Methods
Setting and study design
This study was conducted at Kyoto University Hospital,
a tertiary care 1182-bed university hospital located in
Japan. All patients with bacteremia due to CTXNS-En
that occurred from January 2011 to December 2012
were enrolled in this study. Only the first episode of
bacteremia was included for each patient. Case patients
were defined as adult patients (≥18 years old) with En-
terobacteriaceae isolates non-susceptible to cefotaxime
grown in blood culture. Bacteremia with multiple patho-
gens was excluded. Control patients were matched in a
1:2 ratio to case patients according to the following
algorithm: an adult patient with bacteremia due to
cefotaxime-susceptible Enterobacteriaceae (CTXS-En)
and the infective organism matched to that of the case
patient (Fig. 1). If no matched organism was found, the
organism that belonged to the same genus was selected.
We did not perform routine screening for CTXNS-En
colonization.
Definitions and variables
CTXNS-En isolates with minimum inhibitory concentra-
tions (MICs) of >8 μg/mL were defined as CTXNS-En,
and isolates with MICs ≤8 μg/mL were considered
CTXS-En according to the Clinical and Laboratory Stan-
dards Institute (CLSI) guideline (M100-S19) [9]. Each
patient was classified as hospital-acquired, health care-
associated, or community-acquired in accordance with
the definitions of Friedman et al. [10]. Neutropenia was
defined as an absolute neutrophil count below 500/mm3.
Multidrug-resistant-Enterobacteriaceae (MDR-En) were
defined as Enterobacteriaceae with resistance to 3 or
more different classes of antibiotics [11].
Clinical characteristics included age, sex, underlying
chronic disease, the Charlson weighted index of comor-
bidity [12], immunosuppressive therapy during the pre-
vious 30 days, antibiotic therapy during the previous
30 days, surgery during the previous 30 days, neutro-
penia, the presence of an intravenous catheter or any
other artificial devices, the site of infection, the Sequen-
tial Organ Failure Assessment (SOFA) score [13], the
site of acquisition, and the antimicrobial regimen and
clinical outcomes, including mortality at 30 days.
Antimicrobial therapy was classified into initial empir-
ical and definitive therapy, with the former defined as
initial therapy provided within 72 h after bacteremia on-
set and the latter defined as therapy provided after the
results of susceptibility tests had been reported. Anti-
microbial therapy was considered appropriate when the
isolate was reported as being susceptible to the agent by
the clinical microbiology laboratory.
Clinical outcomes were evaluated daily until 7 days
after starting antimicrobial therapy and were classified
as follows: ‘complete response’ for patients who had
resolved fever, leukocytosis and all signs of infection,
‘partial response’ for patients who had abatement of
abnormalities in the above parameters without complete
resolution and ‘failure’ for patients who had absence of
abatement or who had deterioration in any clinical pa-
rameters or who died.
Microbiological analysis
Blood cultures were incubated on the BacT/Alert system
(bioMérieux, Marcy l’Etoile, France) for 5 days. When
growth was detected, the sample was subcultured and
an isolated colony was used in the subsequent processes.
All isolates and their antibiotic susceptibilities were de-
termined using the MicroScan WalkAway 96 plus sys-
tem (Siemens, Berlin, Germany). ESBL screening was
performed according to the CLSI microdilution method-
ology, with modifications (cefpodoxime, ≥4 μg/mL; cefo-
taxime, ≥8 μg/mL; ceftazidime, ≥2 μg/mL; or aztreonam,
≥8 μg/mL). Quality control was performed using E. coli
ATCC 25922, ATCC 35218 and Pseudomonas aerugi-
nosa ATCC 27853 according to the CLSI document [9].
The confirmation of ESBL production was performed
using cefotaxime-clavulanate and ceftazidime-clavulanate
disks according to the CLSI guideline [9]. The cefoxitin-
cloxacillin disk method was performed to test for chromo-
somal AmpC β-lactamase (c-AmpC) hyperproduction.
Disks containing 30 μg of cefoxitin or 30 μg of cefoxitin
plus 200 μg of cloxacillin were placed on Mueller-Hinton
agar that was inoculated with each isolate, and the speci-
mens were incubated at 37 °C for 16 to 18 h. A difference
in the inhibition zones of cefoxitin and cloxacillin
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compared with cefoxitin alone of ≥4 mm was considered
to be indicative of c-AmpC hyperproduction [14].
Bacterial DNA was isolated using a QIAamp DNA
Mini kit (Qiagen, Hilden, Germany). PCR analyses for
the detection of TEM-, SHV-, and CTX-M-type β-
lactamase genes were conducted as described elsewhere
[15–19]. Plasmid-mediated AmpC β-lactamase (p-AmpC)
was detected using the multiplex PCR method [20] and
was identified by sequencing. Isolates negative for ESBL
and p-AmpC by PCR were then tested using the cefoxitin-
cloxacillin disk method, as described above. Isolates non-
susceptible to imipenem or meropenem (MIC > 1 μg/mL)
were analysed to determine the presence of the carbape-
nemases using multiplex PCR [15]. Primers used for PCR
and sequencing is provided in Additional file 1: Table S1.
Statistical analysis
Comparisons of discrete variables were performed
with Fisher’s exact test, and comparisons of continu-
ous variables were performed using Wilcoxon–Mann–
Whitney tests. The time to a complete response
within 7 days after starting antimicrobial therapy was
analyzed using a Cox-hazard model. To determine the
independent risk factors for CTXNS-En bacteremia
and the time to a complete response, all variables
with p-values of < 0.05 based on univariate analyses
were subjected to further selection using forward
stepwise logistic regression. We forced the inclusion
of the Charlson index, the SOFA score and CTXNS-
En bacteremia in the multivariate models. A p-value
of < 0.05 was considered to be statistically significant.
The statistical analysis was performed using STATA
software version 13 (StataCorporation College Station,
TX, USA).
Results
Risk factors and clinical outcomes
A total of 316 non-duplicate patients with Enterobacteri-
aceae bacteremia were identified during the study
period. Of these, 60 patients (19%) had infections caused
by isolates that showed non-susceptibility to cefotaxime.
Patients with polymicrobial bacteremia (n = 23) were ex-
cluded from the analysis, and 37 patients were analyzed
as the CTXNS-En group. Of the remaining 256 patients
with CTXS-En bacteremia, 32 patients with polymicro-
bial bacteremia were excluded, and 74 patients were
selected as controls. Patients selection process and bac-
terial species were shown in Fig. 1.
The demographics of the patients and risk factors asso-
ciated with bacteremia due to CTXNS-En and CTXS-En
are listed in Table 1. The distributions for age and sex,
severities of illness as measured by SOFA score, and the lo-
cation of acquisition were comparable. Primary bacteremia,
urinary tract infection, and intraabdominal infection were
common sources of infection in both groups.
A risk factor analysis for the CTXNS-En revealed sig-
nificant associations in the univariate analysis with a pre-
vious infection or colonization of CTXNS-En or MDR
bacteria or fluoroquinolone-resistant Enterobacteriaceae,
previous antibiotic use, duration of previous antibiotic
therapy, cardiac disease, transplantation and prior sur-
gery. In the multivariate analysis, previous infection or
colonization of CTXNS-En (odds ratio [OR], 12.32;
95% confidence interval [CI], 3.69–41.12), cardiac dis-
ease (OR, 5.00; CI, 1.64–15.28), the presence of an
intravascular catheter (OR, 5.33; CI, 1.46–19.49) and
prior surgery within 30 days (OR, 4.37; CI, 1.17–
16.41) were independent risk factors for CTXNS-En
bacteremia.
Patients with Enterobacteriaceae bacteremia
(n=316)
Patients with CTXNS-En bacteremia
(n=60)


























Fig. 1 Flow diagram of patient selection process. Three control patients for case patients with E. asburiae (n = 1) and P. penneri (n = 2) were not
found. Patients infected with organism belonging to the same genus were selected as control patients (E. cloacae, n = 1; P. mirabilis, n = 2)
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Univariate analysis Multivariate analysis
OR (95% CI) P-value OR (95% CI) P-value
Age 66 (19–93) 67 (19–90) 0.98
Male 24 (65%) 41 (55%) 0.34
Nosocomial or healthcare-associated bacteremia 34 (92%) 59 (80%) 2.88 (0.73–16.49) 0.17
Previous isolation of MDR bacteria 15 (41%) 9 (12%) 4.92 (1.71–14.51) <0.01
Previous isolation of CTXNS-En 17 (46%) 6 (8%) 9.63 (3.04–33.20) <0.01 12.32 (3.69–41.12) <0.01
Previous isolation of fluoroquinolone-resistant Enterobacteriaceae 11 (30%) 7 (9%) 4.05 (1.26–13.58) 0.01
Previous ICU admission within 30 days 9 (24%) 11 (15%) 1.84 (0.60–5.50) 0.29
Previous antibiotic use within 30 daysa
Any antibiotics 28 (76%) 38 (51%) 2.95 (1.14–8.04) 0.02
Penicillins 2 (5%) 2 (3%) 2.06 (0.14–29.27) 0.60
Third-generation cephalosporins 8 (22%) 7 (9%) 2.64 (0.75–9.36) 0.09
Other cephems 15 (41%) 14 (19%) 2.92 (1.11–7.69) 0.02
β-lactam/β-lactamase inhibitors 6 (16%) 3 (4%) 4.58 (0.90–29.66) 0.06
Carbapenems 6 (16%) 5 (7%) 2.67 (0.62–11.85) 0.18
Fluoroquinolones 6 (16%) 7 (9%) 1.85 (0.47–7.01) 0.35
Aminoglycosides 0 (0%) 1 (1%) 0 1.00
Trimethoprim/sulfamethoxazole 8 (22%) 14 (19%) 1.18 (0.38–3.43) 0.80
Glycopeptides 7 (19%) 6 (8%) 2.61 (0.68–10.17) 0.12
Duration of previous antibiotic use 11 (0–30) 7 (0–30) 0.02
Charlson index 4 (0–9) 3 (0–14) 0.21
Hematological malignancy 7 (19%) 7 (9%) 2.23 (0.60–8.14) 0.22
Solid malignancy 11 (30%) 30 (41%) 0.62 (0.24–1.55) 0.30
Transplantation 10 (27%) 6 (8%) 4.20 (1.22–15.31) 0.01
Hemodialysis 4 (11%) 5 (7%) 1.67 (0.31–8.30) 0.48
Diabetes 9 (24%) 19 (26%) 0.93 (0.33–2.51) 1.00
Cardiac disease 18 (49%) 16 (22%) 3.43 (1.35–8.75) <0.01 5.00 (1.64–15.28) <0.01
Chronic lung disease 8 (22%) 12 (16%) 1.43 (0.45–4.27) 0.60
Liver disease 10 (27%) 17 (23%) 1.24 (0.44–3.33) 0.65
Pancreatobilliary disease 4 (11%) 20 (27%) 0.33 (0.08–1.11) 0.05
Chronic kidney disease 13 (35%) 27 (36%) 0.94 (0.38–2.31) 1.00
Connective tissue disease 4 (11%) 8 (11%) 1.00 (0.21–4.06) 1.00
Intravascular catheter 31 (84%) 40 (54%) 4.39 (1.54–14.26) <0.01 5.33 (1.46–19.49) 0.01
Urinary catheter 16 (43%) 19 (26%) 2.21 (0.88–5.50) 0.08
Mechanical ventilation 6 (16%) 4 (5%) 3.39 (0.73–17.31) 0.08
Other artificial devices 19 (51%) 22 (30%) 2.49 (1.02–6.10) 0.04
Use of immunosuppressive therapy within 30 days 20 (54%) 40 (54%) 1.00 (0.42–2.39) 1.00
Neutropenia 5 (14%) 12 (16%) 0.807 (0.20–2.74) 0.79
Previous surgery within 30 daysb 12 (32%) 6 (8%) 5.44 (1.65–19.34) <0.01 4.37 (1.17–16.41) 0.03
Invasive procedure within 30 days 17 (46%) 18 (24%) 2.64 (1.05–6.63) <0.03
Source of infection
Urinary tract infection 8 (22%) 16 (22%) 1.00 (0.33–2.83) 1.00
Intraabdominal infection 7 (19%) 18 (24%) 0.73 (0.23–2.09) 0.63
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Complete response was achieved within 72 h in 4
(11%) and 23 (31%) of the patients in CTXNS-En and
CTXS-En groups, respectively (Table 2). The CTXNS-
En patients were less likely to receive appropriate empir-
ical antimicrobial therapy than the CTXS-En patients.
Mortality at 30 days was low in both the CTXNS-En
and CTXS-En groups (5 and 3%, respectively).
Univariate analysis using the Cox-hazard model re-
vealed that the variables independently associated with
complete response were the presence of an intravascular
catheter, the SOFA score, empirical carbapenem therapy
and empirical third-generation cephalosporin therapy
(Table 3). In the multivariate analysis, the SOFA score
(hazard ratio [HR], 0.88; CI, 0.80–0.96) and empirical
third-generation cephalosporin therapy (HR, 2.13; CI,
1.30–3.50) were significant predictors of a complete
response.
Microbiological results
The susceptibility testing results for the CTXNS-En
and CTXS-En isolates of the case and control groups
are shown in Table 4. Amikacin and meropenem were
highly active, with greater than 90% of CTXNS-En
isolates being susceptible to them. Susceptibility to
cephalosporins, β-lactam/β-lactamase inhibitor combi-
nations, fluoroquinolones and sulfamethoxazole-
trimethoprim was uncommon in CTXNS-En isolates
compared with CTXS-En isolates, and CTXNS-En iso-
lates more frequently exhibited multidrug resistance
than CTXS-En isolates. Although one K. pneumoniae
isolate and one K. oxytoca isolate had meropenem
MICs of > 1 μg/mL, the multiplex PCR did not detect
the presence of carbapenemases.
ESBL production was confirmed in 20 isolates among
37 CTXNS-En isolates, 19 of which harbored ESBL
gene. All CTXS-En isolates were negative for ESBL con-
firmation test. The types of β-lactamase genes for the
CTXNS-En isolates from the case group are shown in
Table 5. The most prevalent β-lactamase gene harbored
by E. coli was ESBL. In E. coli, blaCTX-M-14 was the most
prevalent gene detected, followed by blaCTX-M-27. In the
K. pneumoniae isolates, both ESBL and p-AmpC genes
were dominant. blaDHA-1 was the only p-AmpC detected
in K. pneumoniae. All but one isolate of Enterobacter
spp. were considered to overproduce c-AmpC. The re-
sistance mechanisms in P. penneri (n = 1) and S. marces-
cens (n = 2) were not determined.
Discussion
The prevalence of CTXNS-En varies across different
geographic regions. A study from Spain revealed that
9.7, 12.5 and 29.1% of third-generation cephalosporin
resistance in bloodstream infections were caused by E.
coli, K. pneumoniae and Enterobacter spp., respectively
[21]. In the SENTRY program study from the United
States of America, the prevalence of third-generation
cephalosporin-resistant Enterobacteriaceae that caused
bacteremia was 6.4% [8]. In the Asia-Pacific region,
approximately 10% of Enterobacteriaceae were pheno-
typically positive for ESBL production [22]. The preva-
lence of CTXNS-En in our study was consistent with
these findings.
Previous antibiotic therapy, especially the use of ceph-
alosporins, has been consistently recognized as a risk
factor for third-generation cephalosporin-resistant En-
terobacteriaceae bacteremia in many studies [2, 3, 6, 23].
Table 1 Univariate and multivariate analyses of risk factors for patients with CTXNS-En and CTXS-En bacteremia (Continued)
Pneumonia 2 (5%) 2 (3%) 2.06 (0.14–29.27) 0.60
Primary bacteremia 14 (38%) 26 (35%) 1.12 (0.45–2.74) 0.84
Other infection 6 (16%) 12 (16%) 1.00 (0.28–3.22) 1.00
SOFA score 3 (0–10) 3 (0–21) 0.34
Data are presented as nos. (%) or medians (interquartile ranges)
MDR multidrug-resistant, OR odds ratio, CI confidence interval
aAll 10 patients who had bacteremia with c-AmpC-overproducing Enterobacteriaceae, including 8 E. cloacae, 1 E. asbriae and 1 C. freundii, were exposed to β-
lactams within 30 days
bThe numbers of patients who had cardiovascular surgery within 30 days were similar in the CTXNS-En and CTXS-En groups (n = 1 [3%] and n = 3 [4%],
respectively; p = 0.72)
Table 2 Univariate analysis of the treatments and outcomes of







Third-generation cephalosporins 5 (14%) 20 (27%) 0.15
Other cephems 10 (27%) 21 (28%) 1.00
β-lactam/β-lactamase inhibitors 11 (30%) 15 (20%) 0.34
Carbapenems 10 (27%) 16 (22%) 0.64
Other antibioticsb 0 (0%) 2 (3%) 1.00
Appropriate empirical therapy 23 (62%) 66 (89%) <0.01
Complete response at 72 h 4 (11%) 23 (31%) 0.02
Complete response at 7 days 23 (62%) 59 (80%) 0.07
30-day mortality 2 (5%) 2 (3%) 0.60
aOne patient died before antibiotics could be administered
bOther antibiotics included amikacin (n = 1) and levofloxacin (n = 1)
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Table 3 Predictors of complete response within 7 days of 111 patients with CTXNS-En and CTXS-En bacteremia
Characteristics Univariate analysis Multivariate analysis
HR (95% CI) P-value HR (95% CI) P-value
Age 1.01 (0.99–1.02) 0.26
Male 1.09 (0.70–1.70) 0.70
Nosocomial or healthcare-associated bacteremia 0.85 (0.48–1.51) 0.58
Charlson index 0.94 (0.85–1.03) 0.20 0.98 (0.89–0.96) 0.74
Hematological malignancy 1.03 (0.53–2.00) 0.93
Solid malignancy 0.95 (0.60–1.49) 0.82
Transplantation 0.65 (0.33–1.30) 0.23
Hemodialysis 0.43 (0.16–1.19) 0.10
Diabetes 1.07 (0.65–1.76) 0.79
Cardiac disease 0.86 (0.54–1.37) 0.52
Chronic lung disease 0.99 (0.56–1.73) 0.96
Liver disease 0.69 (0.40–1.19) 0.18
Pancreatobilliary disease 0.93 (0.55–1.60) 0.81
Chronic kidney disease 0.95 (0.60–1.50) 0.83
Connective tissue disease 0.87 (0.42–1.81) 0.72
Intravascular catheter 0.60 (0.39–0.93) 0.02
Urinary catheter 0.69 (0.42–1.13) 0.14
Mechanical ventilation 0.50 (0.20–1.24) 0.13
Other artificial devices 0.74 (0.46–1.17) 0.20
Use of all immunosuppressive therapy within 30 days 0.90 (0.58–1.39) 0.64
Neutropenia 0.88 (0.47–1.66) 0.70
Previous surgery within 30 days 0.69 (0.37–1.27) 0.23
Invasive procedure within 30 days 0.63 (0.39–1.04) 0.07
Source of infection
Urinary tract infection 1.17 (0.71–1.94) 0.54
Intraabdominal infection 0.72 (0.42–1.23) 0.23
Pneumonia 0.74 (0.23–2.36) 0.62
Primary bacteremia 0.85 (0.53–1.36) 0.50
SOFA score 0.86 (0.79–0.94) <0.01 0.88 (0.80–0.96) <0.01
Empirical therapy
Carbapenems 0.41 (0.22–0.75) <0.01
Third-generation cephalosporinsa 2.54 (1.56–4.14) <0.01 2.13 (1.30–3.50) <0.01
Other cephems 1.32 (0.83–2.10) 0.25
β-lactam/β-lactamase inhibitors 0.66 (0.39–1.11) 0.12
Appropriate empirical therapy 1.43 (0.79–2.58) 0.24
CTXNS-En bacteremia 0.64 (0.39–1.03) 0.07 0.73 (0.45–1.19) 0.20
Data are presented as nos. (%) or medians (interquartile ranges)
One patient with CTXNS-En bacteremia and 2 patients with CTXS-En bacteremia were excluded from the analysis because they died before the achievement of
complete response at 30 days
All variables with p-values less than 0.05 in the univariate analyses were included in the multivariate analysis. Stepwise logistic regression analysis was performed
using forward selection and the likelihood ratio. The Charlson index, SOFA score and CTXNS-En bacteremia were forced into the models
MDR multidrug-resistant, HR hazard ratio, CI confidence interval
aPatients who received third-generation cephalosporin as empirical therapy had lower SOFA scores compared with patients who received other empirical
therapies (median = 2 [range: 0–9] and median = 3 [range: 0–21], respectively; p < 0.01)
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Our study also demonstrated a significant association
between previous antibiotic use and CTXNS-En
bacteremia in the univariate analysis. Prior isolation of
CTXNS-En also appears to be a potent risk factor [4, 6,
24], as shown in our study. These common risk factors
found in both previous studies and our study may help
to identify patients with CTXNS-En bacteremia. Al-
though certain risk factors, including cardiovascular dis-
ease, the presence of intravascular catheters, and prior
surgery within 30 days, suggested cardiovascular surgery
as a risk factor for CTXNS-En bacteremia, prior
cardiovascular surgery within 30 days was comparable
between the CTXNS-En and CTXS-En groups. Patients
with intravascular catheters are more likely to be hospi-
talized patients who receive complicated medical care
and are more likely to acquire antibiotic-resistant patho-
gens. These results suggest that impaired patients who
had undergone surgery had a high risk of acquiring
CTXNS-En bacteremia.
Patients with bacteremia due to drug-resistant Entero-
bacteriaceae have likely received inappropriate empirical
therapy leading to worse mortality [2, 25, 26]. Although
mortality was comparable between the CTXNS-En and
CTXS-En groups in our study, empirical antimicrobial
treatment was more frequently inappropriate among pa-
tients with CTXNS-En bacteremia, and a complete re-
sponse was delayed in the CTXNS-En group compared
with the CTXS-En group. Thus, we used a multivariate
Cox-hazard model for time to complete response to fur-
ther assess the association between CTXNS and delayed
complete response. However, empirical third-generation
cephalosporin therapy was associated with an earlier
complete response. This result can be explained by the
fact that patients who received third-generation cephalo-
sporin as an empirical therapy had lower SOFA scores,
indicating a less severe state of illness, compared with
patients who received other empirical therapies (data
shown in the footnote of Table 3). Other studies have
also found that illness severity appears to be a more sig-
nificant prognostic factor for clinical outcomes than ap-
propriate antibiotic therapy [3, 27–29]. Nonetheless, the
administration of appropriate antibiotic therapy is essen-
tial for the successful treatment of bacteremia, especially
in patients with severe presentations.
In our study, CTXNS-En isolates had high rates of
susceptibility to amikacin and meropenem. Treatments
Table 5 Distribution of resistance mechanisms in 37 CTXNS-En isolates
ESBL p-AmpC c-AmpC
Bacterial species CTX-M-1 groupa CTX-M-2 groupb CTX-M-9 groupc TEM SHVd CMY-2 DHA-1
E. colie (n = 16) 2 0 13 0 0 2 0 0
E. cloacaef (n = 8) 0 0 0 0 1 0 1 7
K. pneumoniaeg (n = 7) 0 1 2 0 1 0 3 0
S. marcescens (n = 2) 0 0 0 0 0 0 0 0
C. freundii (n = 1) 0 0 0 0 0 0 0 1
E. asbriae (n = 1) 0 0 0 0 0 0 0 1
K. oxytoca (n = 1) 0 0 1 0 0 0 0 0
P. penneri (n = 1) 0 0 0 0 0 0 0 0
ablaCTX-M-15 (n = 1), blaCTX-M-55 (n = 1)
bblaCTX-M-2 (n = 1)
cblaCTX-M-14 (n = 8), blaCTX-M-27 (n = 4), blaCTX-M-9 (n = 1) of E. coli, blaCTX-M-14 (n = 2) of K. pneumoniae and blaCTX-M-14 (n = 1) of K. oxytoca
dblaSHV-12 (n = 1), blaSHV-27 (n = 1)
eOne isolate carried blaCTX-M-9 and blaCMY-2
fOne isolate carried blaSHV-12 and blaDHA-1. The other 7 isolates were positive for the c-AmpC hyperproduction test using the cefoxitin-cloxacillin disk method
gOne isolate carried blaSHV-27 and blaCTX-M-14, and 1 isolate did not carry either ESBL or p-AmpC genes
Table 4 Antimicrobial susceptibility of 111 Enterobacteriaceae
isolates recovered from patients with CTXNS-En and CTXS-En
bacteremia





Ceftazidime 5 (14%) 73 (99%) <0.01
Cefozopran 12 (32%) 73 (99%) <0.01
Cefepime 21 (57%) 70 (95%) <0.01
Flomoxefa 22 (59%) 56 (76%) 0.12
Meropenem 36 (97%) 74 (100%) <0.33
Amoxicillin-clavulanate 13 (35%) 46 (62%) <0.01
Piperacillin-tazobactam 25 (68%) 74 (100%) <0.01
Amikacin 37 (100%) 74 (100%) 1.00
Gentamicin 28 (76%) 64 (86%) 0.18
Ciprofloxacin 18 (49%) 65 (88%) <0.01
Levofloxacin 19 (51%) 65 (88%) <0.01
Sulfamethoxazole-trimethoprim 20 (54%) 57 (77%) 0.02
Multidrug resistance 26 (70%) 10 (14%) <0.01
The CLSI breakpoints (M100-S19) were used as interpretive criteria
aIsolates were regarded as susceptible to flomoxef at an MIC of ≤ 8 μg/mL
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other than cefotaxime, such as amikacin or meropenem,
should be considered for patients suspected of Entero-
bacteriaceae bacteremia with risk factors for CTXNS-
En. Two isolates had meropenem MICs of greater than
1 μg/mL. Although carbapenems remain the drugs of
choice for serious infections caused by Enterobacteria-
ceae, there is concern about the rise of carbapenem
resistance in Enterobacteriaceae [30]. Balancing the
appropriateness of therapy and antibiotic overuse is
essential. CTXNS-En isolates were likely to be MDR; co-
resistance to fluoroquinolone is increasing in third-
generation cephalosporin-resistant Enterobacteriaceae
[21, 31]. The use of antimicrobial agents will continue to
create selection pressure that gives MDR-En the oppor-
tunity to become effective intestinal colonizers and pro-
vides opportunities for MDR-En to cause infections with
limited therapeutic options [30]. Continuous monitoring
of MDR-En and antimicrobial stewardship are recom-
mended as important efforts to control MDR-En.
Ninety-four percent of E. coli and 43% of K. pneumo-
niae carried CTX-M-type ESBL genes, the majority of
which encoded CTX-M-14. Whereas CTX-M-15 is the
most widely distributed CTX-M-type ESBL worldwide
[32], CTX-M-14, CTX-M-15 and CTX-M-27 are the
most prevalent ESBL types of E. coli in Asia and Japan
[22, 31]. Previous studies have suggested a low
prevalence of ESBL-producing Enterobacter spp. and C.
freundii in Japan [33, 34], and only one isolate of these
organisms harbored the ESBL gene in our study.
Whereas the predominance of CMY-2 has been de-
scribed worldwide, including in Asia [22, 35], DHA-1 is
the most dominant p-AmpC in K. pneumoniae isolates
in Japan and Asia [22, 36], which is consistent with the
findings of our study. Many Enterobacteriaceae species,
such as Enterobacter spp., Citrobacter spp. and S. mar-
cescens, encode c-AmpC, which can be expressed at high
levels by either induction or selection for derepressed
mutants in the presence of β-lactam antibiotics [35]. All
of the patients who had bacteremia with c-AmpC-
overproducing CTXNS-En were exposed to β-lactam
within 30 days. The resistance mechanism was not deter-
mined in S. marcescens and P. penneri. P. penneri harbors a
class A β-lactamase, HugA, which confers third-generation
cephalosporin-resistance and is regulated by an equivalent
of the amp system, a regulation system of c-AmpC, al-
though we did not assess HugA β-lactamase [37].
There were some potential limitations to this study.
First, the sample size was small, making type II error a
concern. Second, our results were from a single center,
and the prevalence of CTXNS-En isolates likely varies
across institutions, making it difficult to generalize the
prevalence of CTXNS-En in our patients to those at
other institutions. Third, we used the old CLSI break-
point for cefotaxime because the treatment decision was
made based on the old CLSI breakpoint. The revised
CLSI guideline in 2010 adopted a lower breakpoint for
cefotaxime (≤1 μg/ml) [38], which may limit the
generalizability of this study.
Conclusions
CTXNS-En bacteremia is associated with inappropriate
empirical therapy, and the frequent occurrence of a
delay in appropriate therapy likely contributes to inferior
clinical responses. CTXNS-En isolates were likely to be
MDR. Treatments other than cefotaxime, such as amika-
cin or meropenem, should be considered for patients
suspected of Enterobacteriaceae bacteremia with risk
factors for CTXNS-En or severe illness. However, cefo-
taxime may remain the treatment of choice for patients
without these risk factors. Acquired β-lactamases, espe-
cially CTX-M type ESBL, were common in E. coli and
Klebsiella spp., whereas hyperactivation of intrinsic re-
sistance was common in Enterobacter spp.
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